MidAmerica Cancer Center

American Oncology Partners

Kansas City, MO

Sorting 2 by

Not yet accepting

ELRiSE MDS

A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
Learn more
  • Activin Receptor IIA Inhibitor
  • Randomization
  • Phase 3

Not yet accepting

RENEW

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Learn more
  • Activin Receptor IIA Inhibitor
  • Placebo
  • Closed Label (Masked)
  • Phase 3